

Russell H Swerdlow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8593078/publications.pdf>

Version: 2024-02-01

209
papers

18,586
citations

11651
70
h-index

14208
128
g-index

237
all docs

237
docs citations

237
times ranked

21461
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis. <i>Alzheimer's and Dementia</i> , 2023, 19, 333-342.	0.8	78
2	APOE, TOMM40, and sex interactions on neural network connectivity. <i>Neurobiology of Aging</i> , 2022, 109, 158-165.	3.1	8
3	Mitochondrial Membrane Potential Influences Amyloid- β Protein Precursor Localization and Amyloid- β Secretion. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 381-394.	2.6	16
4	Mitochondrial Targeting of Amyloid- β Protein Precursor Intracellular Domain Induces Hippocampal Cell Death via a Mechanism Distinct from Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1727-1744.	2.6	5
5	Pharmacologic enrichment of exosome yields and mitochondrial cargo. <i>Mitochondrion</i> , 2022, 64, 136-144.	3.4	4
6	Regulation of growth, invasion and metabolism of breast ductal carcinoma through CCL2/CCR2 signaling interactions with MET receptor tyrosine kinases. <i>Neoplasia</i> , 2022, 28, 100791.	5.3	6
7	Multimodal strategy to rescue the brain in mild cognitive impairment: Ketogenic oral nutrition supplementation with B vitamins and aerobic exercise. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13806.	3.4	5
8	Mitochondrial function and A β in Alzheimer's disease postmortem brain. <i>Neurobiology of Disease</i> , 2022, 171, 105781.	4.4	11
9	Nonobese Male Patients with Alzheimer's Disease Are Vulnerable to Decrease in Plasma Leptin. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	2.6	3
10	Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients. <i>Alzheimer's and Dementia</i> , 2021, 17, 7-17.	0.8	11
11	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. <i>JAMA Neurology</i> , 2021, 78, 102.	9.0	144
12	Betahydroxybutyrate Consumption in Autopsy Brain Tissue from Alzheimer's Disease Subjects. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 135-141.	2.2	2
13	A ketogenic diet differentially affects neuron and astrocyte transcription. <i>Journal of Neurochemistry</i> , 2021, 157, 1930-1945.	3.9	15
14	Oxaloacetate treatment preserves motor function in SOD1G93A mice and normalizes select neuroinflammation-related parameters in the spinal cord. <i>Scientific Reports</i> , 2021, 11, 11051.	3.3	4
15	Changes in O β GlcNAcylation Alter Mitochondrial Function. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
16	Bioenergetic and inflammatory systemic phenotypes in Alzheimer's disease APOE ϵ 4 carriers. <i>Aging Cell</i> , 2021, 20, e13356.	6.7	11
17	Mild cognitive impairment: when nutrition helps brain energy rescue—a report from the EuGMS 2020 Congress. <i>European Geriatric Medicine</i> , 2021, 12, 1285-1292.	2.8	10
18	CONSENSUS: a Shiny application of dementia evaluation and reporting for the KU ADC longitudinal Clinical Cohort database. <i>JAMIA Open</i> , 2021, 4, ooab060.	2.0	0

#	ARTICLE	IF	CITATIONS
19	Mitochondrial pathway polygenic risk scores are associated with Alzheimer's Disease. <i>Neurobiology of Aging</i> , 2021, 108, 213-222.	3.1	10
20	Mutations in the Amyloid-Î² Protein Precursor Reduce Mitochondrial Function and Alter Gene Expression Independent of 42-Residue Amyloid-Î² Peptide. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1039-1049.	2.6	5
21	Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle. <i>Function</i> , 2021, 2, zqab045.	2.3	9
22	A globally diverse reference alignment and panel for imputation of mitochondrial DNA variants. <i>BMC Bioinformatics</i> , 2021, 22, 417.	2.6	9
23	Mitochondrial links between brain aging and Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 33.	8.0	26
24	Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. <i>Annals of Neurology</i> , 2021, 90, 751-762.	5.3	19
25	APOE, TOMM40, and Sex Interactions on Neural Network Connectivity. <i>Alzheimer's and Dementia</i> , 2021, 17, e058171.	0.8	0
26	Mitochondrial interactions influence Alzheimer's disease risk. <i>Neurobiology of Aging</i> , 2020, 87, 138.e7-138.e14.	3.1	19
27	Detection of mitochondria-pertinent components in exosomes. <i>Mitochondrion</i> , 2020, 55, 100-110.	3.4	30
28	Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 609-633.	46.4	441
29	The mitochondrial hypothesis: Dysfunction, bioenergetic defects, and the metabolic link to Alzheimer's disease. <i>International Review of Neurobiology</i> , 2020, 154, 207-233.	2.0	43
30	Mitochondrial DNA Manipulations Affect Tau Oligomerization. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 149-163.	2.6	15
31	Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients. <i>Alzheimer's and Dementia</i> , 2020, 16, e037962.	0.8	0
32	OGA Inhibition Alters Energetics and Nutrient Sensing in Alzheimer's Disease Cytoplasmic Hybrids. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1743-1753.	2.6	1
33	Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts. <i>Alzheimer's and Dementia</i> , 2020, 16, 1164-1172.	0.8	25
34	Mitochondria in Alzheimer brains. <i>Neurology</i> , 2020, 94, 646-647.	1.1	5
35	Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis. <i>Experimental Neurology</i> , 2020, 330, 113321.	4.1	66
36	An Integrative Overview of Non-Amyloid and Non-Tau Pathologies in Alzheimer's Disease. <i>Neurochemical Research</i> , 2019, 44, 12-21.	3.3	4

#	ARTICLE	IF	CITATIONS
37	Disrupted hippocampal growth hormone secretagogue receptor 1 \pm interaction with dopamine receptor D1 plays a role in Alzheimer's disease. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	45
38	TOMM40 \sim 523 Associations with Baseline and Longitudinal Cognition in APOE ϵ 3 Homozygotes. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 1059-1068.	2.6	5
39	Dietary Neuroketotherapeutics for Alzheimer's Disease: An Evidence Update and the Potential Role for Diet Quality. <i>Nutrients</i> , 2019, 11, 1910.	4.1	37
40	Mitochondria and Alzheimer's: Is PTC1 the Smoking Gun?. <i>Trends in Neurosciences</i> , 2019, 42, 759-762.	8.6	9
41	Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities. <i>British Journal of Pharmacology</i> , 2019, 176, 3489-3507.	5.4	279
42	Current Status of Healthy Aging and Dementia Research: A Symposium Summary. <i>Journal of Alzheimer's Disease</i> , 2019, 72, S11-S35.	2.6	5
43	Mitochondrial Dysfunction and Stress Responses in Alzheimer's Disease. <i>Biology</i> , 2019, 8, 39.	2.8	40
44	An Experimental Ketogenic Diet for Alzheimer Disease Was Nutritionally Dense and Rich in Vegetables and Avocado. <i>Current Developments in Nutrition</i> , 2019, 3, nzz003.	0.3	35
45	Effects of Microglial Cytokines on Alzheimer's Disease-Related Phenomena. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1021-1034.	2.6	7
46	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
47	Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. <i>Muscle and Nerve</i> , 2019, 59, 201-207.	2.2	35
48	Proteomic Analysis and Biochemical Correlates of Mitochondrial Dysfunction after Low-Intensity Primary Blast Exposure. <i>Journal of Neurotrauma</i> , 2019, 36, 1591-1605.	3.4	24
49	Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 28-36.	3.7	199
50	Neuroketotherapeutics: A modern review of a century-old therapy. <i>Neurochemistry International</i> , 2018, 117, 114-125.	3.8	96
51	Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1403-1416.	2.6	500
52	Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases. <i>Cell Death and Differentiation</i> , 2018, 25, 542-572.	11.2	120
53	P4009: TRIAL OF OXALOACETATE IN ALZHEIMER'S DISEASE (TOAD): INTERIM FDG PET ANALYSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1435.	0.8	3
54	P3101: MTDNA HAPLOGROUP ASSOCIATIONS WITH ALZHEIMER'S DISEASE RISK. <i>Alzheimer's and Dementia</i> , 2018, 14, P1106.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Regulation of energy metabolism during early mammalian development: TEAD4 controls mitochondrial transcription. <i>Development (Cambridge)</i> , 2018, 145, .	2.5	32
56	Mitochondrial Function and Neurodegenerative Diseases. , 2018, , 369-414.		1
57	Platelet cytochrome oxidase and citrate synthase activities in APOE ϵ 4 carrier and non-carrier Alzheimer's disease patients. <i>Redox Biology</i> , 2017, 12, 828-832.	9.0	39
58	A bioenergetics systems evaluation of ketogenic diet liver effects. <i>Applied Physiology, Nutrition and Metabolism</i> , 2017, 42, 955-962.	1.9	16
59	A Mitochondrial Biomarker-Based Study of S-Equol in Alzheimer's Disease Subjects: Results of a Single-Arm, Pilot Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 291-300.	2.6	31
60	A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 1463-1470.	4.7	88
61	Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death. <i>Cell Reports</i> , 2017, 20, 2184-2200.	6.4	63
62	Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis. <i>Free Radical Biology and Medicine</i> , 2017, 113, 36-47.	2.9	52
63	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
64	[P3 ϵ 229]: PLATELET MITOCHONDRIA CYTOCHROME OXIDASE AND CITRATE SYNTHASE IN APOE4 ϵ CARRIER AD SUBJECTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1026.	0.8	0
65	Amyloid precursor protein processing and bioenergetics. <i>Brain Research Bulletin</i> , 2017, 133, 71-79.	3.0	143
66	Sustained O-GlcNAcylation reprograms mitochondrial function to regulate energy metabolism. <i>Journal of Biological Chemistry</i> , 2017, 292, 14940-14962.	3.4	79
67	[F3 ϵ 04 ϵ 02]: THE KU ALZHEIMER'S DISEASE KETOGENIC DIET FEASIBILITY AND RETENTION TRIAL: RESULTS FROM A PILOT STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P883.	0.8	1
68	Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration. <i>Frontiers in Immunology</i> , 2017, 8, 508.	4.8	84
69	Arsenite Effects on Mitochondrial Bioenergetics in Human and Mouse Primary Hepatocytes Follow a Nonlinear Dose Response. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-12.	4.0	24
70	Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. <i>PLoS ONE</i> , 2017, 12, e0185926.	2.5	95
71	Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial. <i>PLoS ONE</i> , 2017, 12, e0170547.	2.5	203
72	Bioenergetics and metabolism: a bench to bedside perspective. <i>Journal of Neurochemistry</i> , 2016, 139, 126-135.	3.9	29

#	ARTICLE	IF	CITATIONS
73	Oxaloacetate enhances neuronal cell bioenergetic fluxes and infrastructure. Journal of Neurochemistry, 2016, 137, 76-87.	3.9	44
74	P2-128: Mitochondria and Mitochondrial DNA Induce Neuroinflammation and Alter app Homeostasis. , 2016, 12, P660-P661.		0
75	P3-026: Trial of Sâ€Eequol in Alzheimerâ€™s Disease (SEAD). Alzheimer's and Dementia, 2016, 12, P827.	0.8	0
76	P4-067: Influence of Cell Bioenergetics on App Processing. Alzheimer's and Dementia, 2016, 12, P1039.	0.8	0
77	Loss of NCB5OR in the cerebellum disturbs iron pathways, potentiates behavioral abnormalities, and exacerbates harmaline-induced tremor in mice. Metabolic Brain Disease, 2016, 31, 951-964.	2.9	8
78	Rare <i>ABCA7</i> variants in Alzheimer disease. Neurology, 2016, 86, 2118-2119.	1.1	3
79	The <scp>ABCD</scp>'s of 5â€™adenosine monophosphateâ€activated protein kinase and adrenoleukodystrophy. Journal of Neurochemistry, 2016, 138, 10-13.	3.9	2
80	Extracellular Mitochondria and Mitochondrial Components Act as Damage-Associated Molecular Pattern Molecules in the Mouse Brain. Journal of NeuroImmune Pharmacology, 2016, 11, 622-628.	4.1	34
81	Impaired fasting glucose is associated with increased regional cerebral amyloid. Neurobiology of Aging, 2016, 44, 138-142.	3.1	27
82	Tolerability and pharmacokinetics of oxaloacetate 100mg capsules in Alzheimer's subjects. BBA Clinical, 2016, 5, 120-123.	4.1	24
83	Lactateâ€™s effect on human neuroblastoma cell bioenergetic fluxes. Biochemical Pharmacology, 2016, 99, 88-100.	4.4	12
84	P4-024: Injecting mitochondria into mouse hippocampi induces neuroinflammation and raises app expression. , 2015, 11, P774-P775.		0
85	P4-005: Family history of dementia predicts cognitive decline in cognitively normal subjects. , 2015, 11, P766-P767.		0
86	IC-P-087: Healthy individuals with a family history of Alzheimer's disease have increased default mode network activity. , 2015, 11, P61-P61.		0
87	Mitochondrial Manipulation and the Quest for Alzheimer's Treatments. EBioMedicine, 2015, 2, 276-277.	6.1	4
88	P3-023: Influence of mitochondrial function and cell bioenergetics on app processing. , 2015, 11, P628-P628.		0
89	Mitochondrial Lysates Induce Inflammation and Alzheimer's Disease-Relevant Changes in Microglial and Neuronal Cells. Journal of Alzheimer's Disease, 2015, 45, 305-318.	2.6	67
90	A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 345-352.	1.7	26

#	ARTICLE	IF	CITATIONS
91	<scp>TNF</scp>Î± in cerebral ischemia: another stroke against you?. Journal of Neurochemistry, 2015, 132, 369-372.	3.9	13
92	Effect of one month duration ketogenic and non-ketogenic high fat diets on mouse brain bioenergetic infrastructure. Journal of Bioenergetics and Biomembranes, 2015, 47, 1-11.	2.3	23
93	Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2015, 16, 849-857.	2.1	87
94	Open-source, Rapid Reporting of Dementia Evaluations. Journal of Registry Management, 2015, 42, 111-4.	0.1	10
95	Bioenergetic Dysfunction and Inflammation in Alzheimer's Disease: A Possible Connection. Frontiers in Aging Neuroscience, 2014, 6, 311.	3.4	38
96	Comment: <i>BDNF</i> , fitness, and the brain. Neurology, 2014, 83, 1351-1351.	1.1	2
97	Bioenergetic medicine. British Journal of Pharmacology, 2014, 171, 1854-1869.	5.4	37
98	Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. Human Molecular Genetics, 2014, 23, 637-647.	2.9	79
99	Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. Human Molecular Genetics, 2014, 23, 6528-6541.	2.9	80
100	Altering O-Linked Î²-N-Acetylglucosamine Cycling Disrupts Mitochondrial Function. Journal of Biological Chemistry, 2014, 289, 14719-14730.	3.4	81
101	The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1219-1231.	3.8	557
102	Is Alzheimer's disease a systemic disease?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1340-1349.	3.8	176
103	Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): A paradigm worth exploring. Biochemical Pharmacology, 2014, 88, 573-583.	4.4	13
104	Regulation of Mitochondrial Function and Cellular Energy Metabolism by Protein Kinase C-Î»/Î±: A Novel Mode of Balancing Pluripotency. Stem Cells, 2014, 32, 2880-2892.	3.2	26
105	Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies. Redox Biology, 2014, 2, 619-631.	9.0	117
106	High-field proton magnetic resonance spectroscopy reveals metabolic effects of normal brain aging. Neurobiology of Aging, 2014, 35, 1686-1694.	3.1	60
107	LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis. Experimental Neurology, 2014, 261, 206-216.	4.1	82
108	Effect of high-intensity exercise on aged mouse brain mitochondria, neurogenesis, and inflammation. Neurobiology of Aging, 2014, 35, 2574-2583.	3.1	80

#	ARTICLE	IF	CITATIONS
109	P4-199: IMPACT OF OXALOACETATE ON BRAIN BIOENERGETIC INFRASTRUCTURES, NEUROGENESIS, AND INFLAMMATION. , 2014, 10, P861-P861.		0
110	P1-417: VIGOROUS EXERCISE AFFECTS BRAIN MITOCHONDRIA, NEUROGENESIS, AND INFLAMMATION-RELATED PARAMETERS IN AGED MICE. , 2014, 10, P466-P467.		1
111	Brain biomarkers derived by proton magnetic resonance spectroscopy may indicate brain energetic changes in Alzheimer's disease (643.12). FASEB Journal, 2014, 28, 643.12.	0.5	0
112	Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Human Molecular Genetics, 2013, 22, 3931-3946.	2.9	119
113	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism and Related Disorders, 2013, 19, 869-877.	2.2	119
114	Effect of exercise on mouse liver and brain bioenergetic infrastructures. Experimental Physiology, 2013, 98, 207-219.	2.0	40
115	Backwaters and rapids on the amyloid river. Neurology, 2013, 80, 878-879.	1.1	5
116	Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiology of Disease, 2013, 51, 3-12.	4.4	144
117	Glycolysis-respiration relationships in a neuroblastoma cell line. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2891-2898.	2.4	40
118	Lactate administration reproduces specific brain and liver exercise-related changes. Journal of Neurochemistry, 2013, 127, 91-100.	3.9	91
119	Effect of Cholinergic Signaling on Neuronal Cell Bioenergetics. Journal of Alzheimer's Disease, 2013, 33, 1135-1146.	2.6	7
120	Mitochondrial Haplotypes Associated with Biomarkers for Alzheimer's Disease. PLoS ONE, 2013, 8, e74158.	2.5	28
121	Consumption of Polyphenol Plants May Slow Aging and Associated Diseases. Current Pharmaceutical Design, 2013, 19, 6094-6111.	1.9	27
122	Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic. Human Molecular Genetics, 2012, 21, 4680-4702.	2.9	77
123	Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nature Genetics, 2012, 44, 200-205.	21.4	428
124	Maternal Family History is Associated with Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease, 2012, 31, 659-668.	2.6	53
125	Altered Neurochemical Profile after Traumatic Brain Injury: ¹ H-MRS Biomarkers of Pathological Mechanisms. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 2122-2134.	4.3	107
126	Does Mitochondrial DNA Play a Role in Parkinson's Disease? A Review of Cybrid and Other Supportive Evidence. Antioxidants and Redox Signaling, 2012, 16, 950-964.	5.4	30

#	ARTICLE	IF	CITATIONS
127	Cardiorespiratory fitness is associated with atrophy in Alzheimer's and aging over 2 years. <i>Neurobiology of Aging</i> , 2012, 33, 1624-1632.	3.1	89
128	Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 333-339.	3.8	62
129	Mitochondria and Cell Bioenergetics: Increasingly Recognized Components and a Possible Etiologic Cause of Alzheimer's Disease. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 1434-1455.	5.4	169
130	Mitochondria in Neurodegeneration. <i>Advances in Experimental Medicine and Biology</i> , 2012, 942, 269-286.	1.6	156
131	Mitochondrial Abnormalities in Alzheimer's Disease. <i>Advances in Pharmacology</i> , 2012, 64, 83-126.	2.0	66
132	Alzheimer's Disease Pathologic Cascades: Who Comes First, What Drives What. <i>Neurotoxicity Research</i> , 2012, 22, 182-194.	2.7	59
133	For Apoptists and Tauists, it is time for a sermon from the book of biogenesis. <i>Journal of Neurochemistry</i> , 2012, 120, 347-349.	3.9	7
134	Reduced Mitochondria Cytochrome Oxidase Activity in Adult Children of Mothers with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 483-490.	2.6	85
135	Brain aging, Alzheimer's disease, and mitochondria. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1630-1639.	3.8	251
136	Role and Treatment of Mitochondrial DNA-Related Mitochondrial Dysfunction in Sporadic Neurodegenerative Diseases. <i>Current Pharmaceutical Design</i> , 2011, 17, 3356-3373.	1.9	33
137	Alternate day fasting impacts the brain insulin signaling pathway of young adult male C57BL/6 mice. <i>Journal of Neurochemistry</i> , 2011, 117, 154-163.	3.9	15
138	Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. <i>Neurology</i> , 2011, 76, 822-829.	1.1	88
139	Ncb5or Deficiency Increases Fatty Acid Catabolism and Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2011, 286, 11141-11154.	3.4	31
140	Maternal transmission of Alzheimer's disease: Prodromal metabolic phenotype and the search for genes. <i>Human Genomics</i> , 2010, 4, 170.	2.9	77
141	Polymorphic Variation in Cytochrome Oxidase Subunit Genes. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 141-154.	2.6	28
142	Dysfunctional mitochondria uphold calpain activation: Contribution to Parkinson's disease pathology. <i>Neurobiology of Disease</i> , 2010, 37, 723-730.	4.4	49
143	Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer. <i>Journal of Neurochemistry</i> , 2010, 113, 674-682.	3.9	73
144	Nerve growth factor attenuates oxidant-induced β -amyloid neurotoxicity in sporadic Alzheimer's disease cybrids. <i>Journal of Neurochemistry</i> , 2010, 114, 1605-1618.	3.9	23

#	ARTICLE	IF	CITATIONS
145	Microtubule depolymerization potentiates alpha-synuclein oligomerization. <i>Frontiers in Aging Neuroscience</i> , 2010, 1, 5.	3.4	56
146	Reduced Lean Mass in Early Alzheimer Disease and Its Association With Brain Atrophy. <i>Archives of Neurology</i> , 2010, 67, 428-33.	4.5	303
147	The Alzheimer's Disease Mitochondrial Cascade Hypothesis. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S265-S279.	2.6	435
148	Regulation of neuron mitochondrial biogenesis and relevance to brain health. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 228-234.	3.8	169
149	Hyperglycemia Alters the Schwann Cell Mitochondrial Proteome and Decreases Coupled Respiration in the Absence of Superoxide Production. <i>Journal of Proteome Research</i> , 2010, 9, 458-471.	3.7	56
150	Investigation of Insulin Signaling in Parkinson's Disease Cytoplasmic Hybrid Cells. <i>FASEB Journal</i> , 2010, 24, 1053.6.	0.5	2
151	Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies. <i>Pharmaceuticals</i> , 2009, 2, 150-167.	3.8	43
152	Heat Treatment Improves Glucose Tolerance and Prevents Skeletal Muscle Insulin Resistance in Rats Fed a High-Fat Diet. <i>Diabetes</i> , 2009, 58, 567-578.	0.6	184
153	The Alzheimer's disease mitochondrial cascade hypothesis: An update. <i>Experimental Neurology</i> , 2009, 218, 308-315.	4.1	181
154	DNA extraction procedures meaningfully influence qPCR-based mtDNA copy number determination. <i>Mitochondrion</i> , 2009, 9, 261-265.	3.4	151
155	Oxidative Stress Involvement in α -Synuclein Oligomerization in Parkinson's Disease Cybrids. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 439-448.	5.4	129
156	The Neurodegenerative Mitochondriopathies. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 737-751.	2.6	102
157	Calpain-mediated MPP ⁺ toxicity in mitochondrial DNA depleted cells. <i>Neurotoxicity Research</i> , 2008, 13, 31-38.	2.7	12
158	Mitochondria and ubiquitin-proteasomal system interplay: Relevance to Parkinson's disease. <i>Free Radical Biology and Medicine</i> , 2008, 45, 820-825.	2.9	37
159	Effects of memantine on mitochondrial function. <i>Biochemical Pharmacology</i> , 2008, 75, 956-964.	4.4	27
160	Complex I deficiency in Parkinson's disease frontal cortex. <i>Brain Research</i> , 2008, 1189, 215-218.	2.2	337
161	Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. <i>Mitochondrion</i> , 2008, 8, 219-228.	3.4	102
162	PET sheds light on Alzheimer's disease genetic risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18881-18882.	7.1	9

#	ARTICLE	IF	CITATIONS
163	Cell and animal models of mtDNA biology: progress and prospects. American Journal of Physiology - Cell Physiology, 2007, 292, C658-C669.	4.6	36
164	The Thiazolidinedione Pioglitazone Alters Mitochondrial Function in Human Neuron-Like Cells. Molecular Pharmacology, 2007, 71, 1695-1702.	2.3	112
165	Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?. Neurobiology of Aging, 2007, 28, 1465-1480.	3.1	124
166	Treating Neurodegeneration by Modifying Mitochondria: Potential Solutions to a "Complex" Problem. Antioxidants and Redox Signaling, 2007, 9, 1591-1604.	5.4	68
167	Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. Journal of Neuroscience Research, 2007, 85, 3416-3428.	2.9	120
168	Pathogenesis of Alzheimer's disease. Clinical Interventions in Aging, 2007, 2, 347-59.	2.9	162
169	Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease. Journal of the Neurological Sciences, 2006, 247, 224-230.	0.6	21
170	Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 183-193.	2.6	56
171	SHORT-TERM EFFECT OF DEMENTIA DISCLOSURE: HOW PATIENTS AND FAMILIES DESCRIBE THE DIAGNOSIS. Journal of the American Geriatrics Society, 2006, 54, 1968-1970.	2.6	30
172	Mitochondrial DNA depletion analysis by pseudogene ratioing. Journal of Neuroscience Methods, 2006, 150, 265-271.	2.5	8
173	Differential Regulation of Intracellular Calcium Oscillations by Mitochondria and Gap Junctions. Cell Biochemistry and Biophysics, 2006, 44, 187-204.	1.8	6
174	Mitochondrial dysfunction and caspase activation in rat cortical neurons treated with cocaine or amphetamine. Brain Research, 2006, 1089, 44-54.	2.2	114
175	Molecular characterization of mtDNA depleted and repleted NT2 cell lines. Mitochondrion, 2005, 5, 255-265.	3.4	21
176	Mitochondria dysfunction of Alzheimer's disease cybrids enhances A β toxicity. Journal of Neurochemistry, 2004, 89, 1417-1426.	3.9	258
177	Mitochondria-derived oxidative stress induces a heat shock protein response. Journal of Neuroscience Research, 2004, 78, 420-429.	2.9	49
178	Mitochondrial abnormalities in hybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. Neurobiology of Disease, 2004, 15, 29-39.	4.4	90
179	A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Medical Hypotheses, 2004, 63, 8-20.	1.5	579
180	Dystonia with and without deafness is caused by TIMM8A mutation. Advances in Neurology, 2004, 94, 147-54.	0.8	2

#	ARTICLE	IF	CITATIONS
181	Right Orbitofrontal Tumor With Pedophilia Symptom and Constructional Apraxia Sign. Archives of Neurology, 2003, 60, 437.	4.5	253
182	Mitochondria in Alzheimer's disease. International Review of Neurobiology, 2002, 53, 341-385.	2.0	112
183	Induction of cytochrome c-mediated apoptosis by amyloid β 25-35 requires functional mitochondria. Brain Research, 2002, 931, 117-125.	2.2	102
184	Interaction Among Mitochondria, Mitogen-Activated Protein Kinases, and Nuclear Factor- κ B in Cellular Models of Parkinson's Disease. Journal of Neurochemistry, 2002, 74, 1384-1392.	3.9	109
185	Mitochondrial DNA-Related Mitochondrial Dysfunction in Neurodegenerative Diseases. Archives of Pathology and Laboratory Medicine, 2002, 126, 271-280.	2.5	43
186	Further Evidence for Mitochondrial Dysfunction in Progressive Supranuclear Palsy. Experimental Neurology, 2001, 168, 196-198.	4.1	64
187	Biochemical Analysis of Cybrids Expressing Mitochondrial DNA from Contursi Kindred Parkinson's Subjects. Experimental Neurology, 2001, 169, 479-485.	4.1	43
188	A novel deafness/dystonia peptide gene mutation that causes dystonia in female carriers of Mohr-Tranebjaerg syndrome. Annals of Neurology, 2001, 50, 537-540.	5.3	55
189	Functional mitochondria are required for amyloid β -mediated neurotoxicity. FASEB Journal, 2001, 15, 1439-1441.	0.5	198
190	Disrupted mitochondrial electron transport function increases expression of anti-apoptotic Bcl-2 and Bcl-XL proteins in SH-SY5Y neuroblastoma and in Parkinson disease cybrid cells through oxidative stress. Journal of Neuroscience Research, 2000, 61, 693-700.	2.9	47
191	Alzheimer's disease cybrids replicate β -amyloid abnormalities through cell death pathways. Annals of Neurology, 2000, 48, 148-155.	5.3	171
192	Role of mitochondria in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, 185-190.	1.2	36
193	Abnormal Mitochondrial Morphology in Sporadic Parkinson's and Alzheimer's Disease Cybrid Cell Lines. Experimental Neurology, 2000, 162, 37-50.	4.1	259
194	Use of Cytoplasmic Hybrid Cell Lines for Elucidating the Role of Mitochondrial Dysfunction in Alzheimer's Disease and Parkinson's Disease. Annals of the New York Academy of Sciences, 1999, 893, 176-191.	3.8	88
195	Mitochondrial pathology in Parkinson's disease and implications for therapeutic intervention. Drug Development Research, 1999, 46, 44-50.	2.9	2
196	Mitochondrial abnormalities in non-alcoholic steatohepatitis. Journal of Hepatology, 1999, 31, 430-434.	3.7	449
197	Characterization of Cybrid Cell Lines Containing mtDNA from Huntington's Disease Patients. Biochemical and Biophysical Research Communications, 1999, 261, 701-704.	2.1	35
198	Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Annals of Neurology, 1998, 44, 873-881.	5.3	141

#	ARTICLE	IF	CITATIONS
199	Mitochondrial Dysfunction in Idiopathic Parkinson Disease. American Journal of Human Genetics, 1998, 62, 758-762.	6.2	92
200	Mitochondria and Free Radicals in Neurodegenerative Diseases. American Journal of Human Genetics, 1998, 63, 1567.	6.2	0
201	Cyclosporin A Increases Resting Mitochondrial Membrane Potential in SY5Y Cells and Reverses the Depressed Mitochondrial Membrane Potential of Alzheimer's Disease Cybrids. Biochemical and Biophysical Research Communications, 1998, 248, 168-173.	2.1	98
202	Mitochondria in Sporadic Amyotrophic Lateral Sclerosis. Experimental Neurology, 1998, 153, 135-142.	4.1	159
203	Is NADH Effective in the Treatment of Parkinson's Disease?. Drugs and Aging, 1998, 13, 263-268.	2.7	22
204	Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1997, 1362, 77-86.	3.8	239
205	Origin and functional consequences of the complex I defect in Parkinson's disease. Annals of Neurology, 1996, 40, 663-671.	5.3	619
206	Brain Glucose Metabolism in Alzheimer's Disease. American Journal of the Medical Sciences, 1994, 308, 141-144.	1.1	50
207	Reduction of MPP+-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. NeuroReport, 1994, 5, 2598-2600.	1.2	70
208	Mitochondria and Parkinson's Disease. , 0, , 233-270.		4
209	Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer's Disease. Frontiers in Neuroscience, 0, 16, .	2.8	7